{"name": "Inotek Pharmaceuticals",
 "permalink": "inotek-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/inotek-pharmaceuticals",
 "homepage_url": "http://www.inotekcorp.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@inotekcorp.com",
 "phone_number": "781-676-2100 ",
 "description": "",
 "created_at": "Mon Jun 14 03:56:52 UTC 2010",
 "updated_at": "Fri Jul 30 18:22:37 UTC 2010",
 "overview": "\u003Cp\u003EInotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       27],
      "assets/images/resized/0009/0460/90460v1-max-150x150.jpg"],
     [[185,
       34],
      "assets/images/resized/0009/0460/90460v1-max-250x250.jpg"],
     [[185,
       34],
      "assets/images/resized/0009/0460/90460v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Paul",
      "last_name": "G. Howes",
      "permalink": "paul-g-howes",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "James",
      "last_name": "G. Ham",
      "permalink": "james-g-ham",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$18M",
 "funding_rounds":
  [{"round_code": "d",
    "source_url": "http://www.fiercebiotech.com/story/inotek-gathers-18m-it-plots-phii-trials/2010-06-11?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Inotek gathers $18M as it plots PhII trials  Read more: Inotek gathers $18M as it plots PhII trials",
    "raised_amount": 18000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 6,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Devon Park BioVentures",
         "permalink": "devon-park-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0005/8529/58529v1-max-150x150.png"],
             [[250,
               46],
              "assets/images/resized/0005/8529/58529v1-max-250x250.png"],
             [[450,
               83],
              "assets/images/resized/0005/8529/58529v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Care Capital",
         "permalink": "care-capital",
         "image":
          {"available_sizes":
            [[[110,
               80],
              "assets/images/resized/0004/9581/49581v1-max-150x150.jpg"],
             [[110,
               80],
              "assets/images/resized/0004/9581/49581v1-max-250x250.jpg"],
             [[110,
               80],
              "assets/images/resized/0004/9581/49581v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Pitango Venture Capital",
         "permalink": "pitango-venture-capital",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0001/8978/18978v1-max-150x150.png"],
             [[206,
               73],
              "assets/images/resized/0001/8978/18978v1-max-250x250.png"],
             [[206,
               73],
              "assets/images/resized/0001/8978/18978v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MedImmune Ventures",
         "permalink": "medimmune-ventures",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0004/9449/49449v2-max-150x150.jpg"],
             [[250,
               31],
              "assets/images/resized/0004/9449/49449v2-max-250x250.jpg"],
             [[450,
               57],
              "assets/images/resized/0004/9449/49449v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Rho Capital Partners",
         "permalink": "rho-capital-ventures",
         "image":
          {"available_sizes":
            [[[123,
               73],
              "assets/images/resized/0002/8603/28603v5-max-150x150.jpg"],
             [[123,
               73],
              "assets/images/resized/0002/8603/28603v5-max-250x250.jpg"],
             [[123,
               73],
              "assets/images/resized/0002/8603/28603v5-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "33 Hayden Avenue",
    "address2": "2nd Floor",
    "zip_code": "02421",
    "city": "Lexington",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}